

UROLOGIC ONCOLOGY

Seminars and Original Investigations

Table of Contents: Volume 37, Number 7, July 2019

Review Articles

- 403** **Updates in the molecular epidemiology and systemic approaches to penile cancer**
Jacob J. Adashek, Andrea Necchi and Philippe E. Spiess
- 409** **Communicative aspects of decision aids for localized prostate cancer treatment – A systematic review**
Ruben D. Vromans, Mies C. van Eenbergen, Steffen C. Pauws, Gijs Geleijnse, Henk G. van der Poel, Lonneke V. van de Poll-Franse and Emiel J. Krahmer
- 430** **Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature**
Beat Foerster, David D'Andrea, Mohammad Abufaraj, Stephan Broenimann, Pierre I. Karakiewicz, Morgan Rouprêt, Paolo Gontero, Seth P. Lerner, Shahrokh F. Shariat and Francesco Soria

Clinical - Kidney

- 437** **Management of high complexity renal masses in partial nephrectomy: A multicenter analysis**
Alp Tuna Beksac, Kennedy E. Okhawere, Amr A. Elbakry, Bheesham D. Dayal, David J. Paulucci, Michael B. Rothberg, John P. Sfakianos, Ronney Abaza, Daniel D. Eun, Akshay Bhandari, Ashok K. Hemal, James Porter and Ketan K. Badani
- 445** **Predicting acute kidney injury after robot-assisted partial nephrectomy: Implications for patient selection and postoperative management**
Alberto Martini, John P. Sfakianos, David J. Paulucci, Ronney Abaza, Daniel D. Eun, Akshay Bhandari, Ashok K. Hemal and Ketan K. Badani

Clinical - Testis

- 452** **Preoperative plasma IGFBP2 is associated with nodal metastasis in patients with penile squamous cell carcinoma**
Xiheng Hu, Mingfeng Chen, Wentao Liu, Yangle Li and Jun Fu

Clinical - Bladder

- 462** **Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer**
Liam C. Macleod, Jonathan G. Yabes, Michelle Yu, Mina M. Fam, Nathan E. Hale, Robert M. Turner II, Samia H. Lopa, Jeffrey R. Gingrich, Tudor Borza, Ted A. Skolarus, Benjamin J. Davies and Bruce L. Jacobs
- 470** **The Cancer of the Bladder Risk Assessment (COBRA) score for predicting cancer-specific survival after radical cystectomy for urothelial carcinoma of the bladder: External validation in a cohort of Korean patients**
Hyung Suk Kim, Cheol Kwak, Hyeon Hoe Kim and Ja Hyeon Ku
- 478** **Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder**
Michael Owyong, Yair Lotan, Payal Kapur, Vandana Panwar, Tiffani McKenzie, Thomas K. Lee, Xiaolin Zi, Jeremy W. Martin, Ahmed Mosbah, Hassan Abol-Enein, Mohamed Ghoneim and Ramy F. Youssef

(contents continued on next page)

Table of Contents (*continued*)

Clinical - Prostate

- 485** **Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer**
Kohei Hashimoto, Hidetoshi Tabata, Tetsuya Shindo, Toshiaki Tanaka, Jiro Hashimoto, Ryuta Inoue, Takashi Muranaka, Hiroshi Hotta, Masahiro Yanase, Yasuharu Kunishima, Atsushi Takahashi and Naoya Masumori, on behalf of the Sapporo Medical University Urologic Oncology Consortium (SUOC)
- 492** **Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder**
Ashish Tyagi, Balaji Chandrasekaran, Venkatesh Kolluru, Samarjit Rai, Adrienne C. Jordan, Alatassi Houda, Jamie Messer, Murali Ankem, Chendil Damodaran and Ahmed Haddad

Laboratory - Kidney

- 503** **NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma**
Zuzana Strizova, Pavla Taborska, Dmitry Stakheev, Simona Partlová, Klara Havlova, Stepan Vesely, Jirina Bartunkova and Daniel Smrz
- 510** **BioScore (B7-H1, survivin, and Ki-67) does not predict cancer-specific mortality in surgically treated patients with renal cell carcinoma: An external validation study**
Georg C. Hutterer, Florian Posch, Lorenz Buser, Richard Zigeuner, Laura Morshäuser, Wolfgang Otto, Peter J. Wild, Maximilian Burger, Matthias May, Martin Pichler and Sabine D. Brookman-May